Respivant Sciences is a clinical-stage biopharmaceutical company dedicated to significantly improving the lives of patients suffering from respiratory diseases. Based on promising Phase 2 results, we have initiated a robust Phase 2b clinical trial of our lead candidate, RVT-1601, in patients with idiopathic pulmonary fibrosis (IPF) who suffer from a dry, persistent cough refractory to currently available therapies.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.